Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)
Encontrada(s) 1 página(s)
Dipòsit Digital de la UB
oai:diposit.ub.edu:2445/173199
Dataset. 2021
DATA ON THE EFFECT OF EARLY TREATMENT WITH IVERMECTIN ON VIRAL LOAD, SYMPTOMS AND HUMORAL RESPONSE IN PATIENTS WITH MILD COVID-19
- Chaccour, Carlos
- Casellas, Aina
- Blanco-Di Matteo, Andrés
- Pineda, Iñigo
- Fernández Montero, Alejandro
- Ruiz Castillo, Paula
- Richardson, Mary-Ann
- Rodríguez Mateos, Mariano
- Jordán Iborra, Carlota
- Brew, Joe
- Carmona Torre, Francisco
- Giráldez, Miriam
- Laso, Ester
- Dobaño, Carlota, 1969-
- Moncunill, Gemma
- Yuste, José R.
- Pozo, José L. del
- Rabinovich, Regina
- Schöning, Verena
- Hammann, Felix
- Reina, Gabriel
- Sadaba, Belen
- Fernández Alonso, Miriam
Dades primàries associades a l'article publicat a EClinicalMedicine, vol. 32 [https://doi.org./10.1016/j.eclinm.2020.100720], The trial was conducted in the Pamplona metropolitan area (Navarra, Spain). Patients were enrolled between July 31, 2020 and September 11, 2020 and randomized in a 1:1 ratio to ivermectin (400 mcg/kg) single oral dose or placebo. Assessments on enrollment and at days 4, 7, 14, 21 and 28 post treatment included: general symptoms report, physical examination and adverse events. All patients were asked to complete a daily online diary of symptoms from day 1 to 28 post treatment. On enrollment, as well as on days 7 and 14 blood samples were obtained to assess full blood count, C reactive protein, procalcitonin, ferritin, creatinine phosphokinase, lactic dehydrogenase, troponin T, D dimer, IL-6, and renal function. Viral loads were calculated at enrollment and on days 4, 7, 14 and 21 post treatment based on a nasopharyngeal swab for SARS-CoV-2 PCR (for genes N and E). A semi-quantitative serology for IgG against SARS-CoV-2 was done on samples from all patients on day 21 post-treatment.
Proyecto: //
Buscador avanzado